These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 37051203)
1. Impact of muscular symptoms and/or pain on disease characteristics, disability, and quality of life in adult patients with hypophosphatasia: A cross-sectional analysis from the Global HPP Registry. Dahir KM; Kishnani PS; Martos-Moreno GÁ; Linglart A; Petryk A; Rockman-Greenberg C; Martel SE; Ozono K; Högler W; Seefried L Front Endocrinol (Lausanne); 2023; 14():1138599. PubMed ID: 37051203 [TBL] [Abstract][Full Text] [Related]
2. Burden of Illness in Adults With Hypophosphatasia: Data From the Global Hypophosphatasia Patient Registry. Seefried L; Dahir K; Petryk A; Högler W; Linglart A; Martos-Moreno GÁ; Ozono K; Fang S; Rockman-Greenberg C; Kishnani PS J Bone Miner Res; 2020 Nov; 35(11):2171-2178. PubMed ID: 32654183 [TBL] [Abstract][Full Text] [Related]
3. Effectiveness of asfotase alfa for treatment of adults with hypophosphatasia: results from a global registry. Kishnani PS; Martos-Moreno GÁ; Linglart A; Petryk A; Messali A; Fang S; Rockman-Greenberg C; Ozono K; Högler W; Seefried L; Dahir KM Orphanet J Rare Dis; 2024 Mar; 19(1):109. PubMed ID: 38459585 [TBL] [Abstract][Full Text] [Related]
4. Diagnostic delay is common among patients with hypophosphatasia: initial findings from a longitudinal, prospective, global registry. Högler W; Langman C; Gomes da Silva H; Fang S; Linglart A; Ozono K; Petryk A; Rockman-Greenberg C; Seefried L; Kishnani PS BMC Musculoskelet Disord; 2019 Feb; 20(1):80. PubMed ID: 30764793 [TBL] [Abstract][Full Text] [Related]
5. Clinical profiles of treated and untreated adults with hypophosphatasia in the Global HPP Registry. Dahir KM; Seefried L; Kishnani PS; Petryk A; Högler W; Linglart A; Martos-Moreno GÁ; Ozono K; Fang S; Rockman-Greenberg C Orphanet J Rare Dis; 2022 Jul; 17(1):277. PubMed ID: 35854311 [TBL] [Abstract][Full Text] [Related]
6. Burden of disease in pediatric patients with hypophosphatasia: results from the HPP Impact Patient Survey and the HPP Outcomes Study Telephone interview. Rush ET; Moseley S; Petryk A Orphanet J Rare Dis; 2019 Aug; 14(1):201. PubMed ID: 31419999 [TBL] [Abstract][Full Text] [Related]
7. Characterization of physical, functional, and cognitive performance in 15 adults with hypophosphatasia. Durrough C; Colazo JM; Simmons J; Hu JR; Hudson M; Black M; de Riesthal M; Dahir K Bone; 2021 Jan; 142():115695. PubMed ID: 33069919 [TBL] [Abstract][Full Text] [Related]
8. Frequency and age at occurrence of clinical manifestations of disease in patients with hypophosphatasia: a systematic literature review. Szabo SM; Tomazos IC; Petryk A; Powell LC; Donato BMK; Zarate YA; Tiulpakov A; Martos-Moreno GÁ Orphanet J Rare Dis; 2019 Apr; 14(1):85. PubMed ID: 31023354 [TBL] [Abstract][Full Text] [Related]
10. Biochemical and clinical manifestations in adults with hypophosphatasia: a national cross-sectional study. Hepp N; Frederiksen AL; Duno M; Jørgensen NR; Jensen JB Osteoporos Int; 2022 Dec; 33(12):2595-2605. PubMed ID: 35986118 [TBL] [Abstract][Full Text] [Related]
11. Burden of disease in adult patients with hypophosphatasia: Results from two patient-reported surveys. Weber TJ; Sawyer EK; Moseley S; Odrljin T; Kishnani PS Metabolism; 2016 Oct; 65(10):1522-30. PubMed ID: 27621187 [TBL] [Abstract][Full Text] [Related]
12. Physical Function and Health-Related Quality of Life in Adults Treated With Asfotase Alfa for Pediatric-Onset Hypophosphatasia. Genest F; Rak D; Petryk A; Seefried L JBMR Plus; 2020 Sep; 4(9):e10395. PubMed ID: 32995696 [TBL] [Abstract][Full Text] [Related]
13. Clinical Profiles of Children with Hypophosphatasia prior to Treatment with Enzyme Replacement Therapy: An Observational Analysis from the Global HPP Registry. Martos-Moreno GÁ; Rockman-Greenberg C; Ozono K; Petryk A; Kishnani PS; Dahir KM; Seefried L; Fang S; Högler W; Linglart A Horm Res Paediatr; 2024; 97(3):233-242. PubMed ID: 37442110 [TBL] [Abstract][Full Text] [Related]
14. Effects of asfotase alfa in adults with pediatric-onset hypophosphatasia over 24 months of treatment. Seefried L; Genest F; Petryk A; Veith M Bone; 2023 Oct; 175():116856. PubMed ID: 37481150 [TBL] [Abstract][Full Text] [Related]
15. Investigation of ALPL variant states and clinical outcomes: An analysis of adults and adolescents with hypophosphatasia treated with asfotase alfa. Kishnani PS; Del Angel G; Zhou S; Rush ET Mol Genet Metab; 2021 May; 133(1):113-121. PubMed ID: 33814268 [TBL] [Abstract][Full Text] [Related]
16. Bone mineral density and fracture risk in adult patients with hypophosphatasia. Genest F; Claußen L; Rak D; Seefried L Osteoporos Int; 2021 Feb; 32(2):377-385. PubMed ID: 32879991 [TBL] [Abstract][Full Text] [Related]
17. Asfotase alfa therapy for children with hypophosphatasia. Whyte MP; Madson KL; Phillips D; Reeves AL; McAlister WH; Yakimoski A; Mack KE; Hamilton K; Kagan K; Fujita KP; Thompson DD; Moseley S; Odrljin T; Rockman-Greenberg C JCI Insight; 2016 Jun; 1(9):e85971. PubMed ID: 27699270 [No Abstract] [Full Text] [Related]
18. Clinical and biochemical characteristics of adults with hypophosphatasia attending a metabolic bone clinic. Desborough R; Nicklin P; Gossiel F; Balasubramanian M; Walsh JS; Petryk A; Teynor M; Eastell R Bone; 2021 Mar; 144():115795. PubMed ID: 33301960 [TBL] [Abstract][Full Text] [Related]
20. Impact of socio-demographic and clinical characteristics on functional disability and health-related quality of life in patients with rheumatoid arthritis: a cross-sectional study from Palestine. Al-Jabi SW; Seleit DI; Badran A; Koni A; Zyoud SH Health Qual Life Outcomes; 2021 Oct; 19(1):241. PubMed ID: 34645455 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]